Nano-X Imaging

Nano-X Imaging Ltd. is engaged in the development of medical imaging systems. Its product Nanox System consists of hardware Nanox.ARC and software Nanox.CLOUD that provides image repository, radiologist matching, online and offline diagnostics review and annotation, connectivity to diagnostic assistive artificial intelligence systems, billing, and reporting. The firm operates through the following segments: Nanox.Arc, AI Solutions, and Radiology Services. The company was founded by Ran Poliakine and Hitoshi Masuya in 2011 and is headquartered in Neve Ilan, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Nano-X Imaging reports progress in regulatory clearances and strategic partnerships

Nano-X Imaging showcased progress in regulatory clearances, commercialization efforts, strategic partnerships, and operational optimization during the Q4 2022 Earnings Call.
Despite challenges in regulatory compliance, expenses management, and market competition, the company's strengths in innovation, partnerships, and financial resilience position it well for future growth.
Opportunities for Nano-X Imaging include global expansion, technological advancements, cost efficiencies, and leveraging market demand for imaging solutions.
Overall, Nano-X Imaging's performance in Q4 2022 reflects a strategic focus on growth, innovation, and market expansion in the medical imaging industry.

Nano-X Imaging reports improved Q1 performance and expands global reach

Nano-X Imaging's Q1 2023 performance showed improvement with a reported net loss of $11.8 million and revenue of $2.4 million. The company is focusing on deploying Nanox.ARC globally, strengthening manufacturing capabilities, and expanding market reach through strategic partnerships. Challenges include managing expenses and driving revenue growth to achieve profitability.

Nanox Imaging reports Q2 results, eyes U.S. market growth

Nanox Imaging's Q2 2023 performance reflects investment in growth initiatives, with a focus on market expansion and product deployment.
The company faces financial challenges, including a significant net loss and accrued expenses related to an SEC investigation, necessitating prudent financial management.
Strategic strengths in the U.S. market entry, global commercialization efforts, and strong cash position position Nanox Imaging for future growth and market success.
Opportunities lie in upcoming Investor Day, FDA clearance for Nanox.ARC, and expansion in Africa, offering avenues for revenue growth and market leadership.

Nanox Imaging reports Q3 revenue growth and strategic advancements

Nanox Imaging's Q3 2023 performance showed revenue growth and strategic advancements. While facing financial challenges and potential execution hurdles, the company's focus on expansion and partnerships positions it for future growth.

Nanox Imaging reports Q4 loss, eyes global expansion and AI

Nanox Imaging's Q4 2023 performance showed a mix of revenue growth and strategic investments in technology and market expansion.
The company's strengths lie in its progress with regulatory clearances, commercialization efforts, and success in AI applications.
Challenges include slow AI adoption, implementation hurdles, and the need to overcome barriers to data sharing and transparency.
Opportunities exist in expanding HealthCCS usage, global market presence, and addressing AI adoption challenges for revenue growth.

Nanox Imaging reports Q1 loss, eyes global expansion and AI growth

Nanox Imaging's Q1 2024 performance reflects revenue generation from AI solutions and system sales amid challenges in gross profit margins and a notable net loss.
The company's strategic strengths in partnerships, product launches, and global expansions position it well for future growth and market competitiveness.
While facing challenges in cost management and profitability, Nanox Imaging holds opportunities in expanded indications, market expansions, and AI solutions deployment.

Nano-X Imaging reports Q2 losses, eyes growth through FDA clearances

Nano-X Imaging (NNOX) showcased progress in commercial and clinical fronts but faces challenges in narrowing losses and optimizing operations.
Strategic collaborations, FDA clearances, and global deployment offer opportunities for growth and market expansion.
The focus on transformative imaging solutions and commercial infrastructure acceleration underlines NNOX's commitment to innovation and market leadership.

Nanox Imaging reports mixed Q3 results amidst growth opportunities

Nanox Imaging reported mixed financial results with revenue of $3.0 million and a gross loss of $2.8 million, while achieving record revenue from USARAD business.
The company showcased strengths in technology deployment, partnerships, and clinical trials, but faces challenges in regulatory clearances and financial performance.
Opportunities exist in market expansion, revenue growth, and operational efficiency improvements to drive future success and profitability.
With a strong focus on innovation, partnerships, and market expansion, Nanox is poised for growth but needs to address regulatory hurdles and financial performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nano-X Imaging Ltd. is engaged in the development of medical imaging systems. Its product Nanox System consists of hardware Nanox.ARC and software Nanox.CLOUD that provides image repository, radiologist matching, online and offline diagnostics review and annotation, connectivity to diagnostic assistive artificial intelligence systems, billing, and reporting. The firm operates through the following segments: Nanox.Arc, AI Solutions, and Radiology Services. The company was founded by Ran Poliakine and Hitoshi Masuya in 2011 and is headquartered in Petach Tikva, Israel.

Live Ventures

Boston Beer Company

NEW YORK, NY / ACCESSWIRE / October 8, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court.

Lawsuits Filed Against LIVE, SAM and NNOX - Jakubowitz Law Pursues Shareholders Claims

SAN DIEGO--(BUSINESS WIRE)---- $NNOX #FDA--Nano-X Imaging Ltd. (NNOX) Misrepresented Nanox.ARC's Regulatory and Commercial Prospects

SHAREHOLDER ALERT: Robbins LLP Announces that Nano-X Imaging Ltd (NNOX) is Being Sued for Misleading Shareholders

Sesen Bio Inc.

Yalla Group

NEW YORK, NY / ACCESSWIRE / October 8, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of YALA, SESN and NNOX

SAN FRANCISCO, Oct. 8, 2021 /PRNewswire/ -- Hagens Berman urges Nano-X Imaging Ltd. (NASDAQ: NNOX) investors with significant losses to submit your losses now.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Nano-X Imaging (NNOX) Investors with Losses to Contact Firm's Attorneys Now, Securities Fraud Class Action Filed

NEW YORK--(BUSINESS WIRE)-- #action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Nano-X Imaging Ltd. (“Nano-X” or the “Company”) (NASDAQ: NNOX) in the United States District Court for the Eastern District of New York on behalf of all persons and entities who purchased or otherwise acquired Nano-X securities between June 17, 2021 and August 18, 2021, both dates inclusive (the “Class Period”). Investors h

NANO-X ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Nano-X Imaging Ltd.

SAN DIEGO, Oct. 7, 2021 /PRNewswire/ --  Robbins Geller Rudman & Dowd LLP announces that purchasers of Nano-X Imaging Ltd. (NASDAQ: NNOX) securities between June 17, 2021 and August 18, 2021, inclusive (the "Class Period") have until December 6, 2021 to seek appointment as lead plaintiff in the Nano-X class action lawsuit.

NNOX DEADLINE: Nano-X Imaging Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Hyzon Motors

NEW YORK, NY / ACCESSWIRE / October 7, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

SHAREHOLDER ALERT: LIVE HYZN NNOX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Waterdrop

NEW YORK, NY / ACCESSWIRE / October 6, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court.

CLASS ACTION UPDATE for SESN, WDH and NNOX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

SAN DIEGO--(BUSINESS WIRE)-- #NNOXstock--The suit alleges defendants issued false statements concerning Nano-X business and prospects, resulting in its stock trading at inflated prices.

NNOX ALERT: Nano-X Imaging Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Nano-X Imaging Ltd. (NASDAQ: NNOX) between June 17, 2021 and August 18, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 6, 2021. SO WHAT: If you purchased Nanox securities during the Class Period you

EQUITY ALERT: ROSEN, A LEADING LAW FIRM, Encourages Nano-X Imaging Ltd. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – NNOX

SAN DIEGO, Oct. 5, 2021 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Nano-X Imaging Ltd. ("Nano-X" or the "Company") (NASDAQ: NNOX).

(NNOX) DEADLINE: Did You Suffer a Substantial Loss? Contact Johnson Fistel About Leading Nano-X Imaging Ltd.

Will regulatory issues keep Nano-X from disrupting the medical device industry?

There's a Lot to Like About Nano-X -- and 1 Big Risk

NEVE ILAN, Israel--(BUSINESS WIRE)---- $NNOX #510k--Nanox to announce Zebra-Med secures 8th 510K FDA clearance for its Coronary Artery Calcium solution as part of its population health offering

Nanox to Announce Zebra Medical Vision Secures 8th 510K FDA Clearance for its Coronary Artery Calcium (CAC) Solution as Part of Its Population Health Offering

SHEFAYIM, Israel--(BUSINESS WIRE)-- #510k--Zebra Medical Vision secures 8th FDA clearance for its Coronary Artery Calcium (CAC) solution as part of its population health offering

Zebra Medical Vision Secures 8th FDA Clearance for its Coronary Artery Calcium (CAC) Solution as Part of Its Population Health Offering

Join the Company on Wednesday October 27 th at 8:30am ET to hear about its AI vision and how it can enhance its deep technology

Nanox to Host Live Streaming AI Vision Event

NEW YORK, Sept. 5, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Nano-X Imaging Ltd.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nano-X Imaging Ltd. - NNOX

Company to host webcast on Monday, August 16th at 8:30 am ET Company to host webcast on Monday, August 16th at 8:30 am ET

Nanox to Host Business Update Video Presentation

Nano-X Imaging Ltd (NASDAQ: NNOX) has announced a merger agreement with Zebra Medical Vision Ltd, an artificial medical intelligence (AI) developer, for $100 million upfront and up to another $100 million tied to the achievement of specific milestones. The deal consideration will be paid in Nano-x shares.

Nano-X Imaging Announces Two Acquisitions; Management Reshuffle

Investors are nervous about the company's long-term ability to create shareholder value.

Why Nanox Stock Plunged Today

Nano-X Imaging Ltd (NNOX) CEO Ran Poliakine on Q2 2021 Results - Earnings Call Transcript

KIBBUTZ SHEFAYIM, Israel--(BUSINESS WIRE)-- #AI--In an up-to $200M acquisition by Nanox, Zebra Medical Vision brings its AI to reimagine radiology globally.

In an up-to $200M Acquisition by Nanox, Zebra Medical Vision Brings Its AI to Reimagine Radiology Globally

NEVE ILAN, Israel--(BUSINESS WIRE)---- $NNOX #ai--Nanox Enters into Acquisition via Merger Agreement with Zebra Medical Vision Ltd. and Announces Entry into Binding Letter of Intent with USARAD Holdings Inc. with the Goal of Creating an Integrated, Globally Connected End-to-End Radiology Solution and Population Preventive Health Platform NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical imaging company, announced entry into two agreements intended to create a globally connect

Nanox Enters into Acquisition via Merger Agreement with Zebra Medical Vision Ltd. and Announces Entry into Binding Letter of Intent with USARAD Holdings Inc.

Announces entry into acquisition via m erger agreement with Zebra Medical Vision LTD. and binding letter of intent with USARAD Holdings Inc. to create a globally connected end-to-end radiology solution and p opulation health platform

News for Nano-X Imaging Stock (NNOX)